The Food and Drug Administration (FDA) has approved Ekterly ® (sebetralstat) for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older.

Health groups led by the American Academy of Pediatrics filed a lawsuit against HHS Secretary Robert F. Kennedy Jr. on Monday ...

Ekterly becomes the first FDA-approved oral on-demand treatment for hereditary angioedema in patients aged 12 years and older ...

S&P Global Ratings is considering whether to reclassify Centene Corp.'s credit ratings to junk, which would strongly impact its borrowing power. Centene, the top seller of ACA health plans, is ...

DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) ("DRI Healthcare") today announced KalVista Pharmaceuticals ("KalVista") has disclosed it has received approval from the U.S. Food and Drug ...

As per provisional closing data, the barometer index, the S&P BSE Sensex, added 270.01 points or 0.32% to 83,712.51. The Nifty 50 index rose 61.20 points or 0.24% to 25,522.50.

View the latest KalVista Pharmaceuticals Inc. (KALV) stock price, news, historical charts, analyst ratings and financial information from WSJ.

Starting August 1, exports to the US from Japan, South Korea, Malaysia, Kazakhstan, and Tunisia will face 25% tariffs. Indonesia is set to be hit with a 32% excise duty, while Bangladesh, Cambodia, ...

After delaying a June PDUFA date, the U.S. FDA has approved Kalvista Pharmaceuticals Inc.’s Ekterly (sebetralstat) for hereditary angioedema (HAE) in those aged 12 and older. The plasma kallikrein ...

Trump announced a 25% tariff on goods from South Korea and Japan starting Aug. 1, citing the need to correct for long-standing U.S. trade deficits with the two countries. As of 2024, the goods deficit ...